Publications
Detailed Information
Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Lee, Se Hoon | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Bang, Jae Seug | - |
dc.contributor.author | Paek, Sun Ha | - |
dc.contributor.author | Kim, Suzy | - |
dc.contributor.author | Kim, Il Han | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Dong Gyu | - |
dc.contributor.author | Jung, Hee-Won | - |
dc.contributor.author | Kim, Noe Kyeong | - |
dc.date.accessioned | 2009-11-13T06:08:50Z | - |
dc.date.available | 2009-11-13T06:08:50Z | - |
dc.date.issued | 2002 | - |
dc.identifier.citation | J Neurooncol 60: 171-176 | en |
dc.identifier.issn | 0167-594X (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12635665 | - |
dc.identifier.uri | https://hdl.handle.net/10371/12137 | - |
dc.description.abstract | PURPOSE: To evaluate the efficacy and toxicity of chemotherapy with ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3-nitrosourea) plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. PATIENTS AND METHODS: Between August 1999 and July 2001, previously untreated 30 patients with histologically confirmed glioblastoma multiforme were treated. Chemotherapy consisting of up to 2 cycles of 72 h of continuous intravenous infusion of ACNU (40 mg/m2/day) and cisplatin (40 mg/m2/d) was given over a 6-week period. Radiation was begun 6 weeks after the second cycle of chemotherapy. RESULTS: Median age was 48 years (range 18-66 years) and 22 patients with residual measurable disease after surgery were eligible for response analysis. One (5%) had a complete response (CR), 36% partial response (PR), 14% stable disease (SD), and 45% progressive disease (PD) after chemotherapy. After additional radiation, 22% had CR, 22% PR, 16% SD, and 42% PD. Grades III and IV leukopenia and thrombocytopenia occurred in 18 cycles (36%) and 15 cycles (30%), respectively. No fatal complications occurred. Median time to progression was 5.9 months (95% CI 5.1-6.8 months) and median overall survival was 14.9 months (95% CI 9.1-20.7 months). CONCLUSIONS: Preradiation chemotherapy with ACNU plus cisplatin is effective and feasible in patients with gliobiastoma multiforme. | en |
dc.language.iso | en | - |
dc.publisher | Springer Verlag | en |
dc.subject | Antineoplastic Agents/*administration & dosage/adverse effects | en |
dc.subject | Brain Neoplasms/*drug therapy/mortality/radiotherapy | en |
dc.subject | Cisplatin/*administration & dosage/adverse effects | en |
dc.subject | Combined Modality Therapy | en |
dc.subject | Glioblastoma/*drug therapy/mortality/radiotherapy | en |
dc.subject | Nimustine/*administration & dosage/adverse effects | en |
dc.subject | Survival Analysis | en |
dc.title | Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 최인실 | - |
dc.contributor.AlternativeAuthor | 이세훈 | - |
dc.contributor.AlternativeAuthor | 김태유 | - |
dc.contributor.AlternativeAuthor | 방재석 | - |
dc.contributor.AlternativeAuthor | 백선하 | - |
dc.contributor.AlternativeAuthor | 김수지 | - |
dc.contributor.AlternativeAuthor | 김일한 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.contributor.AlternativeAuthor | 김동규 | - |
dc.contributor.AlternativeAuthor | 정희원 | - |
dc.contributor.AlternativeAuthor | 김노경 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.